– UK, London – ValiRx plc (LON: VAL), a life sciences company focusing on early-stage cancer therapeutics and women’s health, today announced the appointments of Martin Gouldstone and Adrian de Courcey to its Board as Non-Executive Directors with immediate effect.
Concurrently, Ray Horn has been appointed as a Board observer.
About Adrian de Courcey
Adrian de Courcey is a business executive with experience in both corporate and entrepreneurial environments in the UK and internationally. He began his career with KPMG and held strategy roles with Shell and Johnson & Johnson, with experience within the SME sector and built a transportation business. Adrian graduated from the University of Warwick and obtained an MBA from the University of Cambridge in 2020.
About Martin Gouldstone
Martin is currently CEO of Oncimmune Holdings plc and has 30 years of corporate finance and business development experience in contract research organizations, healthcare, and pharmaceutical sectors. Previously, Martin was a Global SVP of Business Development at Owkin, Inc., where he managed commercial teams in the USA and Europe and led new strategic research partnerships. More recently, Martin was CBO at Sensyne Health; Global SVP and Head of Capital Solutions for Syneos Health; CBO at BenevolentAI.
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women’s health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, to achieve a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx’s portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialization.
ValiRx was listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
SOURCE: https://www.valirx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
